Latest Conference Articles

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Analysts, Companies Highlight Key ASCO Research

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

2012 ASCO Pre-Meeting Video Coverage

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

Advanced Coverage Recap: 2012 ASCO Annual Meeting

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Ladenson on Diagnosis of Thyroid Nodules

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult Choices

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

Researchers Find Regional Differences in Stage of Presentation and Survival of Individuals With Thyroid Cancer

Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.

Genetic Data Points to Potential New Therapeutic Target for Adrenocortical Carcinoma

Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.

Why Medical Tattoos Shouldn't Be Taboo

Another presentation at the AACE meeting on Thursday featured Dr. Saleh Aldasouqi, FACE, ECNU, discussing a topic that is not heard about too often in the medical world: tattoos.

Telemedicine a Valuable Way to Deliver Healthcare

Patients who live far from medical facilities benefit from having "virtual" conversations with their doctors and are comfortable with that arrangement.

AACE 21st Annual Scientific and Clinical Congress Slideshow

Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

Oncology Posters Presented at Annual Endocrinology Meeting

A look at two poster presentations from the AACE meeting focusing on insular carcinoma and medullary thyroid cancer.

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine Proves Effective in Breakthrough CINV

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Chapman on BRAF/MEK Combination for Melanoma

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Markman on PCP Awareness of Long-Term Side Effects

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

PCPs Highly Unaware of Long-Term Chemotherapy Side Effects

Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Crizotinib Active in ALK-Positive Pediatric Cancers

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Kazmi Discusses Olanzapine for Breakthrough CINV

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Nurses Discuss the Value of the ONS Annual Congress

Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses.

Video Highlights From the 2012 ONS Congress

The Oncology Nursing Society (ONS) 37th Annual Congress video highlights, from OncLive TV.

ONS 37th Annual Congress Slideshow

The Oncology Nursing Society (ONS) 37th Annual Congress Picture Slideshow.